the Lung Health Canadian Environment (LHCE) study. Can Respir J 2011;18:321–326.

- 9 Gutierrez C, Ghezzo RH, Abboud RT, Cosio MG, Dill JR, Martin RR, et al. Reference values of pulmonary function tests for Canadian Caucasians. Can Respir J 2004;11:414–424.
- 10 Lewthwaite H, Benedetti A, Stickland MK, Bourbeau J, Guenette JA, Maltais F, et al.; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Normative peak cardiopulmonary exercise test responses in Canadian adults aged ≥40 years. Chest 2020;158:2532–2545.
- 11 Khan MN, Pothier CE, Lauer MS. Chronotropic incompetence as a predictor of death among patients with normal electrograms taking beta blockers (metoprolol or atenolol). Am J Cardiol 2005;96:1328–1333.
- 12 Faisal A, Alghamdi BJ, Ciavaglia CE, Elbehairy AF, Webb KA, Ora J, et al. Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. Am J Respir Crit Care Med 2016;193: 299–309.
- 13 Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 2009;301:2024–2035.

- 14 Ong KC, Ng AW, Lee LS, Kaw G, Kwek SK, Leow MK, et al. Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. *Eur Respir J* 2004;24:436–442.
- 15 Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA 2013;310: 1591–1600.
- 16 Amann M, Blain GM, Proctor LT, Sebranek JJ, Pegelow DF, Dempsey JA. Group III and IV muscle afferents contribute to ventilatory and cardiovascular response to rhythmic exercise in humans. J Appl Physiol 2010;109:966–976.
- 17 Gagnon P, Bussières JS, Ribeiro F, Gagnon SL, Saey D, Gagné N, et al. Influences of spinal anesthesia on exercise tolerance in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:606–615.
- 18 Brawner CA, Ehrman JK, Bole S, Kerrigan DJ, Parikh SS, Lewis BK, et al. Inverse relationship of maximal exercise capacity to hospitalization secondary to coronavirus disease 2019. Mayo Clin Proc 2021;96:32–39.

Copyright © 2021 by the American Thoracic Society

Check for updates

Tissue Plasminogen Activator in Critically III Adults with COVID-19

To the Editor:

Hypercoagulability may be a key factor leading to multiorgan failure and death in critically ill patients with coronavirus disease (COVID-19) (1). Extensive pulmonary microthrombi have been described in patients with acute respiratory distress syndrome from COVID-19 (2, 3). These observations have prompted some clinicians to advocate for the use of fibrinolytic therapy with recombinant tissue plasminogen activator (tPA) in select critically ill patients with COVID-19 (4, 5), yet sparse data on safety and efficacy are available (6, 7).

We used data from STOP-COVID (Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19), a multicenter cohort study of critically ill adults with COVID-19 admitted to 68 geographically diverse hospitals across the United States, to examine the safety and efficacy of tPA in this setting (8). We included patients from the STOP-COVID registry admitted to intensive care units (ICUs) between March 1 and July 1, 2020, who received tPA for confirmed pulmonary embolism (PE) or suspected PE or pulmonary microthrombi within 14 days after ICU admission. Patients were followed until hospital discharge or death.

The primary safety endpoint was major bleeding within 7 days of tPA administration, defined as bleeding within a critical area or organ (e.g., intracranial, retroperitoneal, pericardial, or intramuscular bleeding with compartment syndrome) or bleeding requiring a procedural intervention (9). The primary efficacy endpoint was change in the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (Pa_O:FI_O) before and after tPA administration. Secondary efficacy endpoints were the proportion of patients who required therapies for refractory hypoxemia (prone position, neuromuscular blockade, or inhaled pulmonary vasodilators), the proportion of patients with an increase in the Pa_{O_2} :FI_{O2} ratio \geq 50% after tPA administration, and the change in the vasoactive-inotropic score (VIS) in the first 24 hours after tPA administration (10-12). We collected data on the Pa_{Q2}:Fi_{Q2} ratio from the closest arterial blood gas obtained within 48 hours before tPA and the first three arterial blood gases within 48 hours after tPA receipt. We collected VIS data immediately before and at 6, 12, and 24 hours after tPA receipt.

Among 5,154 patients enrolled in STOP-COVID, 93 (1.8%) received tPA. We excluded patients who received tPA for intracatheter thrombosis (n = 28), peripheral arterial thrombosis (n = 2), ischemic stroke (n = 2), myocardial infarction (n = 1), or catheter-directed thrombolysis (n = 1), leaving a total of 59 patients (from 16 institutions) included in this analysis.

Baseline characteristics of these 59 patients (1.1% of the parent cohort) are shown in Table 1. The median age was 60 years (interquartile range [IQR], 50–67), 43 (72.9%) were male, and 19 (32.2%) were White. A total of 58 patients (98.3%) were receiving invasive mechanical ventilation at the time of tPA administration, 43 (72.9%) were receiving vasoactive medications, and 8 (13.6%) were receiving renal replacement therapy for acute kidney injury. The median Pa_{O_2} :FIO₂ ratio at the time of tPA receipt was 86 (IQR, 69–157), and 30 patients (50.8%) were receiving at least one therapy for refractory hypoxemia. PE was radiologically confirmed in 12 patients (20.3%); the remaining 47 patients (79.7%) had suspected PE or pulmonary microthrombi. Six patients (10.2%) received tPA during a cardiac arrest, and all six of these patients died. The median time from ICU admission to tPA administration was 4 days (IQR, 1–8), the median total dose of tPA was

³ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern.

Supported by the following grants from the National Institutes of Health: R01HL144566 and R01DK125786 (D.E.L.), K08GM134220 and R03AG060179 (S.S.), K23HL130648 (K.S.M.), K23DK124645 (L.C.), and K08ES031678 (J.R.).

Author Contributions: D.J.D., S.S., J.R., and D.E.L. conceived the study, had full access to the data in the study, and take responsibility for the integrity of the data and accuracy of the analyses. D.J.D. and D.E.L. wrote the manuscript. D.J.D., I.P., and D.E.L. designed the table and figure. D.J.D., S.S., S.K.B., and D.E.L. acquired the data. All authors provided feedback on the protocol and critically revised and approved the final version of the manuscript.

Table 1. Patient characteristics, tPA administration, and outcomes

Age: ",r. inedian (IOR) 60 (50-67) Box, M., n (%) 43 (72.9) Race, n (%) 19 (22.0) Dift or unknown 27 (45.8) Hispanic, n (%) 18 (30.5) DMI, median (IOR) 22 (27.6-36.8) Comotbillies, n (%) 21 (55.5) JBM, median (IOR) 24 (57.6) Comotbillies, n (%) 4 (63.9) Diabetes mellitus 21 (55.6) Hypanension 34 (57.6) Corrollies, n (%) 4 (63.9) Consequiture disease 6 (10.2) Atrial fibrilation or atrial future 5 (8.5) Congestive heart failure 5 (5.1) Chronoxy atring disease 3 (5.1) Leaktory mobility, gdia 13.1 (11.5-13.8) D-dimor, ngmi 15 (8.2-15.7) Hemoglobin, gdia 13.1 (11.1-5-13.8) D-dimor, ngmi 10.000 (3.822-25.966) Leakter, moubl. 23 (1.6-3.4) C-reactive protein, mg/L 18 (82-15.7) Hemoglobin, gdia 13.1 (12.1-13.8) D-dimor, ngmi 15 (8.2-15.7) Hemoglobin,	Characteristic	tPA Recipients ($n = 59$)
Six, h_n (%)43 (72.9)White19 (32.2)Back13 (22.0)Back13 (22.0)Wayner, h_n (%)21 (25.6)Dillatedes multiple22 (27.6–36.8)Comorbidities, n_n (%)22 (27.6–36.8)Comorbidities, n_n (%)21 (35.6)Diabetes multiple21 (35.6)Hypertension24 (6.8)Control diverse moder14 (23.4)Control diverse	Demographics	/
Pace, n (%)19 (32.2)While19 (32.2)Black13 (22.0)Other or unknown27 (45.8)Hispanic, n (%)18 (30.5)Black13 (22.0)Collabeles melline27 (45.9)Hispanic, n (%)32.2 (27.6-36.8)Collabeles melline24 (57.6)COPD4 (6.6)Current or former smoker14 (23.4)Coronary artery disease6 (10.2)Chronic kildery visites at Hare5 (8.5)Coronary artery disease3 (5.1)Chronic kildery visites at Hare25 (21.1-313)Dedites melline11 (11.3-13.8)Platelet countrimm ³ 254 (21.1-313)Dedites melline10,000 (3.32.2-25.966)Lactate, mmol/L2.3 (1.1-3.24)Dedites melline1.4 (82.2-15.7)Platelet countrimm ³ 254 (21.1-313)Dedites melline1.4 (87.4-264)Creactive protein, mg/L148 (74-264)Ferritin, ng/ml1.094 (63.2-2.0.48)Ferritin, ng/ml1.094 (63.2-2.0.48)International normalized ratio1.3 (1.1.2-1.4)Partiel thromolypaint times, t. n %)36.5 (22.5-66.9)Invasive mechanical ventilation50 (88.3)Vascoressores43 (72.9)Acute renal replacement therapy42 (71.2)Headin initiation25 (42.4)Frindingen in truston50 (25-100)Intial bolts does, mg50 (25-100)Intial bolts does, mg50 (25-100)Intial bolts does, mg50 (25-100)Intial bolts		
White 19 (32.2) Black 13 (22.0) Other or unknown 27 (45.3) Hispanic, 1%) 18 (30.5) BMI, median (ICR) 22 (27.6-36.8) Comotbidiles, 1(%) 21 (35.6) Didbetes mellitus 21 (35.6) Didbetes mellitus 24 (6.8) Coronary disease 4 (6.8) Coronary dires medication or strill futter 5 (8.5) Coronary dires at PA receipt, median (ICR) 11.6 (8.2-15.7) Leukocyte count/mm ² 11.6 (8.2-15.7) Hemoglobin, gldl 13.1 (11.3-13.8) Platelet count/mm ² 25.6 (21.1-31.3) Datamer, ngrull 23 (16.3-4) Corractive protein, mg/L 12.6 (47-258) Ferritin, ngrull 1.994 (639-20.48) Floringen, mg/dl 1.3 (1214) International corralization 1.3 (1214) Patient enal replacement therapy 26 (42.4-366) Floringen, mg/dl 1.3 (1214) Floringen, mg/dl 1.3 (1214) Floringen, mg/dl 1.3 (1214) International cormalistion 1.3 (43 (72.9)
Black 13 (2.0) Other or unknown 27 (45.8) Hispanic, n (%) 18 (30.5) BMI, median (IQF) 22 (27.8–36.8) Camorbidilities, n (%) 21 (35.6) Diabetes mailtus 21 (35.6) Current or former smoker 4 (67.6) Current or former smoker 6 (10.2) Attail flobilition or attail flutter 5 (8.5) Cornoary artery disease 3 (5.1) Chronic kidney disease 3 (5.1) Chronic kidney disease 3 (5.1) Define (QP) 11 (8 (82–15.7) Ladoratory values at PA receipt, median (IQR) 13 (11.8–13.8) Ladoratory values at PA receipt, median (QR) 13 (11.8–13.8) Definer, ng/ml 10 (40 (633–2.6.966) Ladoratory values at PA receipt, median (IQR) 23 (11–3.13) Definer, ng/ml 1.094 (633–2.0.48) Ferritin, ng/ml 1.094 (633–2.0.48) Ferritin, ng/ml 1.094 (633–2.0.48) Ferritin, ng/ml 1.094 (633–2.0.48) Ferritin, ng/ml 1.094 (633–2.0.48) Ferritin Intorobilasin time, s 3 (72.9)		10 (20 0)
Other or unknown 27 (45.3) Hispanic, (%) 16 (30.5) BMI, median (IQR) 22 (27.6–36.8) Outobalties, (%) 1 Diabetes mellitus 21 (35.6) Hyperinsion 21 (57.6) Current or former smoker 41 (23.4) Corrent or former smoker 6 (10.2) Atrial fibrillation or atrial flutter 5 (6.5) Congestive heart failure 3 (5.1) Exboratory values at PA receipt, median (ICP) 11 (6.2) Leukocyte count/mm ² 11 (6.2) Platelat counf/mm ² 10 (000 (3.22) Outing might 10 (000 (3.22) Leukocyte count/mm ² 264 (211-31.3) Dedmer, ngmit 10 (000 (3.22) Leukocyte count/mm ² 10 (000 (3.22) Platelat count/mm ² 264 (211-31.3) Dedmer, ngmit 10 (24.42-39.3) Formiongen, mg/dl 10 (4.63.2-0.48) Fibringen, mg/dl 10 (4.64.2-766) Hibranice 13 (12-1.4) Partial thromboplastin time, s 36.16.0 Sovenet of incoagulation at tPA receipt, n (%)		
Hispanic, n (%)18 (30.5)BMI, median (IQR)32.2 (27.6-36.8)Comorbidities, n (%)21 (35.6)Hypertension34 (67.6)COPD4 (6.8)Current or former smoker4 (6.8)Current or former smoker4 (6.8)Current or former smoker4 (6.8)Current or former smoker6 (10.2)Atrial fibriliation or atrial flutter5 (6.5)Chronic kidney disease3 (5.1)Laboratory values at IPA receipt, median (IQR)11.6 (8.2–15.7)Laboratory values at IPA receipt, median (IQR)254 (21.1–313)Laboratory values at IPA receipt, median (IQR)2.3 (16–3.4)Latotate, mmolt2.3 (16–3.4)D-dimer, ng/ml1.094 (639–2.048)Latatate, mmolt1.094 (639–2.048)Ferritin, ng/ml1.094 (639–2.048)Fibringen, mg/dl1.3 (12–1.4)Pattelet count/mm ³ 58 (22.5–68.9)Settry of lines at IPA receipt, n (%)11.6 (8.2–1.4)Therapeutic-dose anticoagulation at IPA receipt, n (%)11.7Therapeutic-dose anticoagulation at IPA receipt, n (%)12 (20.3)Patelet countinon replacement therapy25 (42.4)Envapores.26 (33.6)VV-ECMO1.2 (20.3)Patelet duinnonary embolism20 (25–100)Heapin infusion50 (25–100)Heapin infusion50 (25–100)History of the duinnonary embolism20 (25–100)Patelet count of the receipt of the duinnonary embolism20 (25–100)Histor Intervous system1.6 (16.7)<		
BMI, median (IQR) 32 (27.6-36.8) Diabetes mellitus 21 (35.6) Diabetes mellitus 34 (57.6) COPD 4 (6.8) COPD 4 (6.8) Cornary arery disease 6 (10.2) Atrial fibrillation or atrial flutter 5 (8.5) Cornary arery disease 3 (5.1) Chronic Kidny disease 3 (5.1) Laboratory values at IP a receipt, median (IQR) 11 (8 (8.2–15.7) Hemoglobin, gidl 13 (11.3–13.8) Pletelet countrom ² 24 (211-313) D-dimer, ngmin 10,000 (3.822–25.966) Lactate, mmol/L 40 (342–34) C-reactive protein, mg/L 148 (74–258) Ferritin, ngmin 1,000 (329–2,048) International normalized ratio 13,1 (2–1.4) Partial throboplastin time, s 35 (5 (29–56.9) Severity of illness at IPA receipt, n (%) 11 (7) International normalized ratio 14 (36,1) Vascopressors 43 (72.9) Acute renal replacement therapy 2 (42.4) V42 (20.3) 2 (42.4) Parapault-codese an		
Comorbidities, n (%) Diabetes mellitus 21 (35.6) Hypertension 24 (6.8) COPD 14 (23.4) Coronary attry disease 45 (21.2) Coronary attry disease 45 (21.2) Attrial fibrillation or attrial flutter 5 (8.5) Coronations kidney disease 45 (21.2) Chronic kidney disease 45 (21.2) Chronic kidney disease 45 (21.2) Chronic kidney disease 45 (21.2) Chronic kidney disease 47 (21.2) Leukocyte count/mm ² Platelet count/mm ² D-dimer, ng/ml Ladate, mmol.L O-dimer, ng/ml Ladate, mmol.L O-dimer, ng/ml Ladate, mmol.L O-dimer, ng/ml Ladate, mmol.L O-dimer, ng/ml Ladate, mmol.L O-dimer, ng/ml Ladate, mmol.L O-dimer, ng/ml Hiernational normalized ratio Flaving mg/dl International normalized ratio Flaving mg/dl International normalized ratio International normalized ratio International normalized ratio International complexity of (23.2) Particle renal replacement therapy VV-ECMO International therapy VV-ECMO International to PA receipt, n (%) Any Hepatin infusion Encoxaparin IPA administration, median (1CP) Days from ICU admission to IPA receipt, n (%) IPA administration, median (1CP) Days from ICU admission to IPA receipt IPA administration, median (1CP) Major bleeding VL dater tPA, n (%) Site of mapproblem Infusion Ime, h Actior therapy the difference of the display of (33.3) Invasive menostatic intervention for bleeding Invasive free of the ration in the of tPA Antipitated therapy at the of tPA Antipitated therapy that lor important contributor to death Major bleeding VL dater tPA, n (%) Characteristics in the of tPA Antipitated therapy that lor important contributor to death Pac, mm Hy, median (1CP) Coronation of ventilation pre-tPA/post-tPA* Site of (33.3) Therapeutic anticoapulation at the of tP		
Hypertension 24 (57.6) COPPD 4 (6.8) Current or former smoker 14 (23.4) Coronary attry disease 6 (10.2) Attrial fibrillation or attrial futter 5 (8.5) Congestive heart failure 3 (5.1) Chronic kidney disease 3 (5.1) Laboratory values at tPA receipt, median (IOR) 13 (11.3 - 11.3.8) Leukocyte count/mm ³ 13.0 (21.3.8) Platelet count/mm ⁴ 254 (211-31.3) D-dimer, ng/m 10.00 (3.382-25.966) Lactate, mmo/L 24 (63-2) (48.4) C-reactive protein, mg/L 148 (74-25.6) Ferritin, ng/m 1,044 (033-2,048) Florinogen, mg/L 649 (484-79.6) Formational normational normation of the sat tPA receipt, n (%) 36.5 (22.5-68.9) Navaive mechanical ventilation 58 (98.3) Vasopressors 40 (72.9) Acute renal replacement therapy 42 (71.2) VV-ECMO 1 (1.7) Therapeutic-dose anticoagulation at tPA receipt, n (%) 7 (79.7) Confirmed pulmonary embolism 7 (79.7) Confirmed pulmonary embolism	Comorbidities, n (%)	
COPD4 (6.8)Current or former smoker14 (23.4)Coronary attery disease6 (10.2)Atrial fibrillation or atrial futter5 (8.5)Congestive heart failure3 (5.1)Chronic kidney disease3 (5.1)Laboratory values at IPA receipt, median (IOR)11.6 (8.2–15.7)Hemoglobin, g/dl13.1 (11.3–13.8)Platelie Count/mm ³ 254 (211–313)D-dimer, ng/ml10.000 (3.382–25.966)Lactate, mmold.2.3 (16–3.4)C-reactive protein, mg/L2.3 (16–3.4)Ferritin, ng/ml1.094 (639–2.048)Florinogen, mg/dl1.094 (639–2.048)Florinogen, mg/dl1.3 (1.2–1.4)Partial thromboplastin time, s85 (28.5–68.9)Svevrity of liness at IPA receipt, n (%)11.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)11.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)11.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)11.7)Therapeutic-dose anticoagulation to tPA receipt, n (%)11.7)PA administration, median (DA)25 (42.4)Hexator, n (%)17 (28.8)PA administration, median (DA)25 (42.4)PA administration, median (DA)20 (6-100)Main threadow, n (%)11.7)PA administration, median (DA)20 (6-100)PA administration, median (DA)6 (10.2)PA administration, median (DA)26 (42.4)PA administration, median (DA)26 (43.3)PA administration, median (DA)26 (33.3)	Diabetes mellitus	
Current or former smoker14 (23.4)Coronary artery disease6 (10.2)Artial fibrillation or atrial flutter5 (8.5)Congestive heart failure3 (5.1)Chronic kidney disease3 (5.1)Leukocyte count/mm ³ 13.1 (11.3-13.8)Platelet count/mm ⁴ 10.000 (3.382–25,966)Lactate, mmol/L254 (211–313)D-dimer, ng/ml10.000 (3.382–25,966)Lactate, mmol/L2.3 (1.6–3.4)C-reactive protein, mg/L148 (74–258)Ferritin, ng/ml1.094 (633–2,048)Fibrinogen, mg/L649 (484–796)International normalized ratio1.3 (1.2–1.4)Partial thromobolastin time, s36.5 (29.5-68.9)Severity of illness at IPA receipt, n (%)56 (98.3)Invasive mechanical venitation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy25 (42.4)Partial thromobolastin time, s25 (42.4)Partiauthromobolastin time, s25 (42.4)Partiauthromobolastin time, s25 (42.4)Acute renal replacement therapy41 (3.6)VV-ECMO11 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)11 (20.3)Any25 (42.4)Partiauthromobolism12 (20.3)UPA indication, n (%)50 (50–100)Suspected pulmonary embolism20 (53.3)Confirmed pulmonary embolism26 (33.3)Confirmed pulmonary embolism26 (33.3)Confirmed pulmonary embolism26 (33.3)Contacteristics of bleeding, n/n bleed (
Coronary artery disease6 (10.2)Arrial fibrillation or atrial futter5 (8.5)Congestive heart failure3 (5.1)Laboratory values at IPA receipt, median (IQR)11.6 (8.2–15.7)Laboratory values at IPA receipt, median (IQR)13.1 (11.3–13.8)Phatelet count/mm³254 (211–313)D-dimer, ng/ml10.000 (3.382–25.966)Lactate, mmol/L2.3 (16–3.4)C-reactive protein, mg/L148 (74–258)Ferritin, ng/ml1.049 (633–2.048)Fibrinogen, mg/dl649 (484–796)International normalized ratio13.1 (2.1–4.4)Partial thromboplastin time, s36.5 (29.5–68.9)Severity of lines at IPA receipt, n (%)11.7)International compliated ratio58 (98.3)V-Severity of lines at IPA receipt, n (%)11.7)Therapeutic-dose anticoagulation at IPA receipt, n (%)25 (42.4)Acute renal replacement therapy25 (42.4)VV-ECMO11.7)Therapeutic-dose anticoagulation at IPA receipt, n (%)7 (79.7)Confirmed pulmonary embolism47 (79.7)Confirmed pulmonary embolism6 (10.2)PA administration, median (UCR)6 (10.2)Characteristics of bleeding, n/n bleed (%)26 (33.3)Major bleeding26 (33.3)Major bleeding26 (33.3)Confirmed pulmonary embolism26 (33.3)<		
Atrial fibrillation or atrial flutter5 (6.5)Congestive heart failure3 (5.1)Chronic kidney disease3 (5.1)Leukocyte count/m³11.6 (8.2–15.7)Hemoglobin, g/dl13. (11.3–13.8)Platelet count/ma*254 (211–31.3)D-dimer, ng/m110.000 (3.382–25.966)Lactate, mmol/L2.3 (1.6–3.4)C-reactive protein, mg/L48 (74–258)Ferritin, ng/m11.094 (639–2.048)Fibrinogen, mg/dl649 (484–796)International normalized ratio1.3 (1.2–1.4)Partial thromobolastin time, s36.5 (29.5–68.9)Severity of illness at IPA receipt, n (%)1Invasive mechanical ventilation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1Therapeutic-dose anticoagulation at IPA receipt, n (%)1Any2Pa Indiction, n (%)1Suspected pulmonary embolism2 (20.3)UPA Indication, n (%)50 (50–100)Unital book dose, mg50 (50–100)Initial book dose, mg50 (50–100)Initial book dose, mg50 (50–100)Initial book dose, mg2 (6 (33.3)Centrade during cardiac arrest, n (%)6 (10.2)Major bleeding with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)26 (33.3)Site of major bleeding2/6 (33.3)Invasive herrows system6/6 (3.3)Centrade during cardiac arrest, n (%)6/6 (3.3)Major bleed		
Congestive heart failure3 (5.1)Chronic kidney disease3 (5.1)Laboratory values at IPA receipt, median (IQR)11.6 (8.2–15.7)Leukocyte count/mm313.1 (11.3–13.8)Platelet count/mm3254 (211–313)D-dimer, ng/ml10.000 (3.382–25.966)Lactate, mmol/L2.3 (1.6–3.4)C-reactive protein, ng/L148 (74–258)Ferritin, ng/ml1.094 (633–2.048)Fibrinogen, mg/dl649 (484–796)International normalized ratio13.1 (2–1.4)Parial thrombopasitin time, s36.5 (28.5-68.9)Severity of lines at IPA receipt, n (%)58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)1 (20.3)PA indication, n (%)1 (20.3)PA indication, n (%)1 (20.3)UPA administration, median (UGR)6 (0–14)Confirmed pulmonary embolism2 (20.3)IPA administration in edian (UGR)50 (25–100)Initial bola dose, mg50 (25–100)Initial bola dose, mg50 (25–100)Initial bola dose, mg50 (25–100)Initial bola dose, mg2 (6 (33.3)Centrared during cardiac arrest, n (%)6 (10.2)Major bleeding with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, in/ bleed (%)2 (6 (33.3)Site of major bleed2 (6 (33.3)Centrate during cardiac arrest,		
Chrönic kidney disease3 (5.1)Leukozyte count/m³11.6 (8.2–15.7)Hemoglobin, g/dl13.1 (11.3–13.8)Platelet count/m³254 (211–313)D-dimer, ng/nl10.000 (3.382–25.966)Lactate, mmol/L2.3 (1.6–3.4)C-reactive protein, mg/L148 (74–258)Ferritin, ng/ml1.094 (639–2.048)Fibrinogen, mg/dl1.094 (639–2.048)International normalized ratio1.3 (1.2–1.4)Partial thromboplasiti time, s35.5 (29.5–68.9)Severity of lines at LPA receipt, n (%)11.7)Invasive mechanical ventilation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)11.7)Any42 (71.2)Heparin infusion25 (42.4)Enoxaparin17 (28.8)tPA administration, median (ICP)20 (50–100)Uridication, n (%)20 (50–100)Days from ICU admission to tPA receipt6 (0–14)Cumulative dose, mg50 (25–100)Initiasion tized arrest, n (%)6 (10.2)Major bleeding26 (33.3)Major bleeding26 (33.3)Major bleeding26 (33.3)Invasive hemostatic intervention for bleeding26 (33.3)Invasive hemostatic intervention for bleeding26 (33.3)IPA indication, ni (%)21 (6.13.3)IPA administered during cardiac arrest, n (%)6 (10.2)Continue A dose, mg50 (25–100)Initiati		
Laboratory values at tPA receipt, median (IQR) Leukocyte count/mm ³ Platelet count/mm ³ Dedimer, ng/ml Lactate, mmol/L Lactate, mmol/L Lactate, mmol/L C-reactive protein, mg/L C-reactive protein, mg/L Fibrinogen, mg/dl International normalized ratio A (2 - 2 - 4) Partial thromboplastin time, s Severity of liness at tPA receipt, n (%) Invasive mechanical ventilation V-SEOMO A (2 - 2) Acute renal replacement therapy VV-EGMO A (2 - 2) Acute renal replacement therapy A (2 - 2) A (2 - 1) A (2 - 1) A (1 - 2) A (2 - 1) A (2 - 1) A (1		
Leukocyte count/mm³11.6 (8.2–15.7)Hemoglobin, g/dl13.1 (11.3–13.8)Platelet count/mm³254 (211–313)D-dimer, ng/ml10.000 (3382–25.966)Lactate, mmol/L2.3 (1.6–3.4)C-reactive protein, mg/L148 (74–258)Ferritin, ng/ml1.94 (639–2.048)Fibrinogen, mg/dl649 (484–796)International normalized ratio1.3 (1.2–1.4)Partial thromboplastin time, s36 (29.5–68.9)Severity of illness at tFA receipt, n (%)43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)2 (71.2)Heparin infusion25 (42.4)Enoxaparin17 (28.8)TPA administration, metaling (IQR)6 (0–14)Confirmed pulmonary embolism7 (79.7)Confirmed pulmonary embolism50 (25–100)Infusion ting, h50 (25–100)Infusion ting, h50 (25–100)Infusion ting, h50 (25–100)Infusion ting, h2 (1–2)Administered during cardiac arest, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)2/6 (33.3)Site of major bleeding2/6 (33.3)Central nervous system1/8 (16.7)Major bleeding2/6 (33.3)Invasive herrosstatic intervention for bleeding2/6 (33.3)Invasive herrosstatic intervention for bleeding2/6 (33.3)Invasive herrosstatic intervention for bleeding		
Platelit countrim254 (211-313)D-dimer, ng/ml10,000 (3,382-25,966)Lactate, mmol/L2.3 (1.6-3.4)C-reactive protein, ng/L148 (74-258)Ferritin, ng/ml1.094 (639-2,048)Fibrinogen, mg/dl649 (484-796)International normalized ratio1.3 (1.2-1.4)Partial thromboplastin time, s36.5 (22.5-68.9)Severity of liness at tPA receipt, n (%)1Invasive mechanical ventilation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)1Ariy25 (42.4)Enoxaparin12 (20.3)Heparin infusion25 (42.4)Enoxaparin12 (20.3)UPA administration, median (IQR)1Days from ICU admission to tPA receipt6 (0-14)Confirmed pulmonary embolism2 (1-2)HPA administration, median (IQR)2 (1-2)Jayrin bite during cardiac arrest, n (%)6 (10.2)Initial bolus dose, mg50 (25-100)Initiab olus dose, mg50 (25-100)Initiation time, h2 (1-2)Major bleeding26 (33.3)Characteristics of bleeding, nh bleed (%)Site of major bleed26 (33.3)Invasive hemostatic intervention for bleeding26 (33.3)Intable during cardiac arrest, n (%)6 (10.2)Major bleed ing nh or bleed (%)26 (33.3)Intable during cardiac arrest, n (%)6 (10.2)Majo	Leukocyte count/mm ³	
D-dimer, ng/ml 10,000 (3,382–25,966) Lactate, mmol/L 148 (74–258) C-reactive protein, ng/L 148 (74–258) Ferritin, ng/M 1094 (639–2,048) Fibrinogen, mg/dl 649 (484–786) International normalized ratio 13 (12–14) Partial thromboplastin time, s 36.5 (29,5-68.9) Severity of illness at tPA receipt, n (%) 13 (12–14) Acute renal replacement therapy 43 (72.9) Acute renal replacement therapy 8 (13.6) VV-ECMO 1 (1.7) Therapeutic-dose anticoagulation at tPA receipt, n (%) 17 (28.8) Any 42 (71.2) Heparin infusion 12 (20.3) Enoxaparin 17 (28.8) TPA administration, median (IQR) 12 (20.3) Ura daministration, median (IQR) 20.3 Ura diministration during cardiac arrest, n (%) 6 (0–14) Major bleeding 50 (50–100) Initiatio blue dose, mg 50 (50–100) Initiatio low dose, mg 50 (50–100) Initiation low, h 2 (1–2) Administered during cardiac arrest, n (%) <td< td=""><td>Hemoglobin, g/dl</td><td></td></td<>	Hemoglobin, g/dl	
Lactate, minol/L2.3 (1.6–3.4)C-reactive protein, mg/L148 (74–258)Ferritin, ng/ml1,094 (639–2,048)International normalized ratio1.3 (1.2–1.4)Partial thromboplastin time, s36.5 (29.5-68.9)Severity of liness at LPA receipt, n (%)1Invasive mechanical ventilation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)22 (71.2)Heparin infusion25 (42.4)Enoxaparin12 (20.3)tPA indication, n (%)42 (71.2)Hoparin infusion25 (42.4)Enoxaparin12 (20.3)tPA indication, n (%)42 (71.2)Marking and the probabilism12 (20.3)tPA administration, median (ICR)10.94 (63.3)Days from ICU admission to tPA receipt6 (0-14)Comfirmed pulmonary embolism2 (2.3)tPA administration, median (iCR)2 (1-2)Major bleeding6 (10.2)Initial bolus dose, mg50 (25–100)Initial bolus dose, mg6 (10.2)Major bleeding with 7 d after tPA, n (%)6 (10.2)Major bleeding with 7 d after tPA, n (%)26 (33.3)Characteristics of bleeding, <i>nin</i> bleed (%)26 (33.3)Site of major bleed26 (33.3)Characteristics of bleeding, <i>nin</i> bleeding26 (33.3)Received red cell transfusion for bleeding26 (33.3)Received red cell transfusion for bleeding26 (33.3) </td <td></td> <td></td>		
C-reactive protein, mg/L148 (74–258)Ferritin, ng/ml1,094 (639–2:048)Fibrinogen, mg/dl649 (484–796)International normalized ratio1.3 (1.2–1.4)Partial thromboplastin time, s36.5 (29.5-68.9)Severity of illness at tPA receipt, n (%)8Invasive mechanical ventilation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)42 (71.2)Heparin infusion25 (42.4)Enoxaparin25 (42.4)Enoxaparin17 (28.8)VPA indication, n (%)7 (79.7)Confirmed pulmonary embolism7 (79.7)Confirmed pulmonary embolism50 (25–100)Intial bolis dose, mg50 (25–100)Initial bolis dose, mg50 (25–100)Initial bolis dose, mg50 (25–100)Initial bolied mg th 7 d after tPA, n (%)6 (10.2)Major bleeding there during cardiac arrest, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)2/6 (33.3)Site of major bleed2/6 (33.3)Central nervous system1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion to tPA atomitisteristical1/6 (16.7)Major bleed ing with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)		
Ferritin, ng/ml1,094 (639-2,048)Fibrinogen, mg/dl649 (484-796)International normalized ratio1,3 (1,2-1,4)Partial thromboplastin time, s36.5 (29,5-68.9)Severity of ilness at IPA receipt, n (%)88 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at IPA receipt, n (%)42 (71.2)Heparin infusion25 (42.4)Enoxaparin17 (28.8)tPA indication, n (%)47 (79.7)Confirmed pulmonary embolism12 (20.3)tPA administration, median (IGR)50 (55-100)Initial bolus dose, mg50 (56-100)Initial bolus dose, mg50 (25-100)Initial bolus dose, mg6 (10.2)Major bleeding6 (10.2)Major bleeding26 (33.3)Central nervous system1/6 (16.7)Major bleeding2/6 (33.3)Central nervous system1/6 (16.7)Mucocutaneous2/6 (33.3)Received red cell transfusion for tPA0/6 (30.3)Received red cell transfusion for bleeding2/6 (33.3)Received red cell transfusion for bleeding5/6 (83.3)Received red cell transfusion fo		
Fibrinoger, mg/dl649 (484-796)International normalized ratio1.3 (1.2–1.4)Partial thromboplastin time, s36.5 (29.5-68.9)Severity of ilness at tPA receipt, n (%)8Invasive mechanical ventilation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)42 (71.2)Any42 (71.2)Heparin infusion57 (42.4)Enoxaparin17 (28.8)TPA administration, median (IQR)79.7)Confirmed pulmonary embolism47 (79.7)Confirmed pulmonary embolism77 (77.7)Confirmed pulmonary embolism50 (50-100)Initial bolus dose, mg50 (25-100)Initial bolus dose, mg50 (25-100)Initial bolus dose, mg6 (10.2)Major bleeding6Major bleeding with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)2/6 (33.3)Site of major bleed fill1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Receiv		
International normalized ratio1.3 (1.2–1.4)Partial thromboplastin time, s36.5 (29.5-68.9)Severity of illness at tPA receipt, n (%)58 (98.3)Invasive mechanical ventilation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)42 (71.2)Any42 (71.2)Heparin infusion25 (42.4)Enoxaparin17 (28.8)VFA indication, n (%)79.7)Suspected pulmonary embolism12 (20.3)UPA administration, median (IQR)12 (20.3)Days from ICU admission to IPA receipt6 (0–14)Cumulative dose, mg50 (50–100)Influiat bolus dose, eng50 (25–100)Influiat bolus dose, mg6 (10.2)Major bleeding76 (33.3)Centrate during cardiac arrest, n (%)6 (10.2)Major bleeding with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)2/6 (33.3)Site of major bleed2/6 (33.3)Centrate nervous system1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Invasive dose of tPA, mg, median (IQR)50 (50-8)Administered curvetion for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Received red cell		
Partial thromopolastin time, s36.5 (29.5-68.9)Severity of illness at tPA receipt, n (%)58 (98.3)Invasive mechanical ventilation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)42 (71.2)Heparin infusion25 (42.4)Enoxaparin17 (28.8)tPA indication, n (%)42 (79.7)Confirmed pulmonary embolism12 (20.3)tPA administration, median (IQR)50 (50-100)Days from ICU admission to tPA receipt6 (0-14)Cumulative dose, mg50 (25-100)Influis out time, h2 (1-2)Administrated during cardiac arrest, n (%)6 (10.2)Major bleeding6 (10.2)Site of major bleed2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Invas		
Severity of illness at tPA receipt, n (%)Invasive mechanical ventilation58 (98.3)Vasopressors43 (72.9)Acute renal replacement therapy8 (13.6)VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)42 (71.2)Any42 (71.2)Heparin infusion25 (42.4)Enoxaparin25 (42.4)PA indication, n (%)7 (79.7)Confirmed pulmonary embolism47 (79.7)Confirmed pulmonary embolism12 (20.3)tPA administration, median (IQR)50 (50-100)Days from ICU admission to tPA receipt6 (0-14)Cumulative dose, mg50 (52-100)Infusion time, h2 (1-2)Administered during cardiac arrest, n (%)6 (10.2)Major bleeding6 (10.2)Characteristics of bleeding2/6 (33.3)Ereceived real mensus system1/6 (16.7)Gastrointestina16 (16.7)Gastrointestina16 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bl		
Vasopressors 43 (72.9) Acute renal replacement therapy 8 (13.6) VV-ECMO 1 (1.7) Therapeutic-dose anticoagulation at tPA receipt, n (%) 42 (71.2) Any 42 (71.2) Heparin infusion 25 (42.4) Enoxaparin 17 (28.8) PA indication, n (%) 12 (20.3) Suspected pulmonary embolism 47 (79.7) Confirmed pulmonary embolism 50 (50-100) IPA administration, median (IQR) 6 (0-14) Cumulative dose, mg 50 (50-100) Initial bolus dose, mg 50 (25-100) Initial bolus dose, mg 50 (25-100) Initial bolus dose, mg 6 (10.2) Major bleeding 6 (10.2) Major bleeding with 7 d after tPA, n (%) 6 (10.2) Characteristics of bleeding, n/n bleed (%) 5 Site of major bleed 1/6 (16.7) Gastrointestinal 1/6 (16.7) Mucocutaneous 2/6 (33.3) Invasive hemostatic intervention for bleeding 2/6 (33.3) Invasive hemostatic intervention for bleeding 2/6 (33.3) Received red cell transfusion or bleeding 2/6 (33.3)	Severity of illness at tPA receipt, n (%)	
Acuté renal replacement therapy 8 (13.6) VV-ECMO 1 (1.7) Therapeutic-dose anticoagulation at tPA receipt, n (%) 42 (71.2) Any 42 (21.2) Heparin infusion 25 (42.4) Enoxaparin 17 (28.8) tPA indication, n (%) 47 (79.7) Suspected pulmonary embolism 47 (79.7) Confirmed pulmonary embolism 47 (79.7) Confirmed pulmonary embolism 6 (0–14) Days from ICU admission to tPA receipt 6 (0–14) Cumulative dose, mg 50 (50–100) Initial bolus dose, mg 50 (25–100) Initial bolus dose, mg 50 (25–100) Indigor bleeding 6 (10.2) Major bleeding 6 (10.2) Site of major bleed 50 (50–100) Site of major bleed 6 (10.2) Site of major bleed 6 (10.2) Major bleeding 2/6 (33.3) Central nervous system 1/6 (16.7) Gastrointestinal 1/6 (16.7) Mucocutaneous 2/6 (33.3) Invasive hemostatic intervention for bleeding 2/6 (33.3) Received red cell transfusion tor bleeding 2/6 (33.3) Received red cel transfusion for bleeding 2/6 (33.3) Received red cel transfusion for bleeding 2/6 (33.3		
VV-ECMO1 (1.7)Therapeutic-dose anticoagulation at tPA receipt, n (%)42 (71.2)Any42 (71.2)Heparin infusion25 (42.4)Enoxaparin17 (28.8)tPA indication, n (%)47 (79.7)Confirmed pulmonary embolism12 (20.3)tPA administration, median (IQR)6 (0-14)Days from ICU admission to tPA receipt6 (0-14)Cumulative dose, mg50 (50-100)Infusion time, h2 (1-2)Administered during cardiac arrest, n (%)6 (10.2)Major bleeding6 (10.2)Major bleeding n/n bleed (%)2/6 (33.3)Site of major bleed1/6 (16.7)Boronchopulmonary2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Invasive hemostatic intervention for bleeding5/6 (83.3)Invasive hemostatic i		
Therapeutic-dose anticoagulation at tPA receipt, n (%)42Any42 (71.2)Heparin infusion25 (42.4)Enoxaparin17 (28.8)tPA indication, n (%)42 (70.2)Suspected pulmonary embolism47 (79.7)Confirmed pulmonary embolism12 (20.3)tPA administration, median (IQR)6 (0–14)Days from ICU admission to tPA receipt6 (0–14)Cumulative dose, mg50 (50–100)Initial bolus dose, mg50 (25–100)Infusion time, h2 (1–2)Administered during cardiac arrest, n (%)6 (10.2)Major bleeding6 (10.2)Major bleeding16 (16.7)Site of major bleed2/6 (33.3)Eronchopulmonary2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Maccutaneous2/6 (33.3) <t< td=""><td></td><td></td></t<>		
Any42 (71.2)Heparin infusion25 (42.4)Enoxaparin17 (28.8)tPA indication, n (%)47 (79.7)Suspected pulmonary embolism12 (20.3)tPA administration, median (IQR)6 (0-14)Days from ICU admission to tPA receipt6 (0-14)Cumulative dose, mg50 (50-100)Initial bolus dose, mg50 (25-100)Initial bolus dose, mg6 (10.2)Major bleeding6 (10.2)Major bleeding6 (10.2)Major bleeding2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA0/6 (0)Major bleed red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA0/6 (0)Major bleed of the therapy at time of tPA0/6 (0)Major bleed red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA0/6 (0)Major bleed of the therapy at time of tPA0/6 (0)Major bleed of the therapy at time of tPA0/6 (0)Major bleed of the therapy at time of tPA0/6 (0)Mujor bleed cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA0/6 (0)Major bleed cell transfusion for bleeding2/6 (35.0)Cumulative dose of tPA, mg, median (IQR)50 (50-		1 (1.7)
Heparin infusion25 (42.4)Enoxaparin17 (28.8)PA indication, n (%)47 (79.7)Suspected pulmonary embolism47 (79.7)Confirmed pulmonary embolism47 (79.7)Days from ICU admission to tPA receipt6 (0–14)Cumulative dose, mg50 (50–100)Initial bolus dose, mg50 (25–100)Initial bolus dose, mg50 (25–100)Infusion time, h2 (1–2)Administered during cardiac arrest, n (%)6 (10.2)Major bleeding6Major bleeding with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)2/6 (33.3)Site of major bleed2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA5/6 (60.0)Major bleed of the during the diagonal at origonal contributor to death3/6 (50.0)Contral nervous system2/6 (33.3)Contral nervous deal or time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA5/6 (50.0)Major bleed of the during or the diagonal contributor to death3/6 (50.0)Conduction and ventilation pre-tPA/post-tPA*50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*5/6 (50.0)Cardia and the diagonal contributor to death3/6 (50.0)Cardia and torigonal contribut		42 (71.2)
Enoxaparin17 (28.8)tPA indication, n (%)47 (79.7)Suspected pulmonary embolism12 (20.3)tPA administration, median (IQR)12 (20.3)Days from ICU admission to tPA receipt6 (0–14)Cumulative dose, mg50 (50–100)Initial bolus dose, mg50 (25–100)Infusion time, h2 (1–2)Administered during cardiac arrest, n (%)6 (10.2)Major bleeding6 (10.2)Major bleeding with 7 d after tPA, n (%)6 (10.2)Site of major bleed2/6 (33.3)Bronchopulmonary2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA0/6 (0)Major bleed clearly fatal or important contributor to death3/6 (50.0)Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60–107) / 80 (56–103)		
tPA indication, n (%)47 (79.7)Suspected pulmonary embolism12 (20.3)tPA administration, median (IQR)12 (20.3)Days from ICU admission to tPA receipt6 (0–14)Cumulative dose, mg50 (50–100)Initial bolus dose, mg50 (25–100)Initial bolus dose, mg6 (10.2)Major bleeding6 (10.2)Major bleeding6 (10.2)Characteristics of bleeding, n/n bleed (%)6 (10.2)Site of major bleed2/6 (33.3)Bronchopulmonary2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA0/6 (0)Major bleed celarly fatal or important contributor to death3/6 (50.0)Curulative dose of tPA, mg, median (IQR)84 (60–107) / 80 (56–103)		
Confirmed pulmonary embolism12 (20.3) tPA administration, median (IQR) 6 Days from ICU admission to tPA receipt 6 Cumulative dose, mg 50 Initial bolus dose, mg 50 Initial bolus dose, mg 50 Infusion time, h 2 Administered during cardiac arrest, n (%) 6 Major bleeding 6 Major bleeding with 7 d after tPA, n (%) 6 Characteristics of bleeding, n/n bleed (%) 6 Site of major bleed $2/6$ Bronchopulmonary $2/6$ Castrointestinal $1/6$ Mucocutaneous $2/6$ Invasive hemostatic intervention for bleeding $2/6$ Invasive hemostatic intervention for bleeding $2/6$ Therapeutic anticoagulation at time of tPA $0/6$ Major bleed clearly fatal or important contributor to death $3/6$ Cumulative dose of tPA, mg, median (IQR) 84 Cumulative dose of tPA, mg, median (IQR) 84 Cumulative dose $1/8$ Cumulative dose $1/9$, formCurve train and ventilation pre-tPA/post-tPA* $3/6$ Curve train and ventilation pre-tPA/post-tPA* $3/6$ <td< td=""><td>tPA indication, n (%)</td><td></td></td<>	tPA indication, n (%)	
tPA administration, median (IQR) Days from ICU admission to tPA receipt $6 (0-14)$ Cumulative dose, mg $50 (50-100)$ Initial bolus dose, mg $50 (25-100)$ Infusion time, h $2 (1-2)$ Administered during cardiac arrest, $n (%)$ $6 (10.2)$ Major bleeding $6 (10.2)$ Major bleeding with 7 d after tPA, $n (%)$ $6 (10.2)$ Characteristics of bleeding, n/n bleed (%) $2/6 (33.3)$ Site of major bleed $2/6 (33.3)$ Bronchopulmonary $2/6 (33.3)$ Central nervous system $1/6 (16.7)$ Gastrointestinal $1/6 (16.7)$ Mucoutaneous $2/6 (33.3)$ Invasive hemostatic intervention for bleeding $2/6 (33.3)$ Received red cell transfusion for bleeding $2/6 (33.3)$ Therapeutic anticoagulation at time of tPA $0/6 (0)$ Major bleed clearly fatal or important contributor to death $3/6 (50.0)$ Cumulative dose of tPA, mg, median (IQR) $50 (50-88)$ Oxygenation and ventilation pre-tPA/post-tPA* $84 (60-107) / 80 (56-103)$		
Days from ICU admission to tPA receipt $6 (0-14)$ Cumulative dose, mg $50 (50-100)$ Initial bolus dose, mg $50 (25-100)$ Initial bolus dose, mg $2 (1-2)$ Administered during cardiac arrest, n (%) $6 (10.2)$ Major bleeding $6 (10.2)$ Major bleeding with 7 d after tPA, n (%) $6 (10.2)$ Characteristics of bleeding, n/n bleed (%) $50 (25-100)$ Site of major bleed $7 (46 (16.7))$ Gastrointestinal $1/6 (16.7)$ Mucocutaneous $2/6 (33.3)$ Invasive hemostatic intervention for bleeding $2/6 (33.3)$ Invasive nerostatic intervention for bleeding $2/6 (33.3)$ Therapeutic anticoagulation at time of tPA $5/6 (83.3)$ Antiplatelet therapy at time of tPA $0/6 (0)$ Major bleed clearly fatal or important contributor to death $3/6 (50.0)$ Cumulative dose of tPA, mg, median (IQR) $50 (50-103)$		12 (20.3)
Cumulative dose, mg $50 (50-100)$ Initial bolus dose, mg $50 (25-100)$ Infusion time, h $2 (1-2)$ Administered during cardiac arrest, $n (\%)$ $6 (10.2)$ Major bleeding $6 (10.2)$ Major bleeding with 7 d after tPA, $n (\%)$ $6 (10.2)$ Characteristics of bleeding, n/n bleed (%) $51 (6 (33.3))$ Site of major bleed $2/6 (33.3)$ Bronchopulmonary $2/6 (33.3)$ Central nervous system $1/6 (16.7)$ Gastrointestinal $1/6 (16.7)$ Mucocutaneous $2/6 (33.3)$ Invasive hemostatic intervention for bleeding $2/6 (33.3)$ Therapeutic anticoagulation at time of tPA $5/6 (83.3)$ Antiplatelet therapy at time of tPA $5/6 (83.3)$ Major bleed clearly fatal or important contributor to death $3/6 (50.0)$ Cumulative dose of tPA, mg, median (IQR) $50 (50-88)$ Oxygenation and ventilation pre-tPA/post-tPA* $84 (60-107) / 80 (56-103)$		C(0, 14)
Initial bolus dose, mg50 (25-100)Infusion time, h2 (1-2)Administered during cardiac arrest, n (%)6 (10.2)Major bleeding6 (10.2)Major bleeding with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)50 (26-102)Site of major bleed76 (33.3)Bronchopulmonary2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA0/6 (0)Major bleed clearly fatal or important contributor to death3/6 (50.0)Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60-107) / 80 (56-103)		
Infusion time, h2 (1-2)Administered during cardiac arrest, n (%)6 (10.2)Major bleeding6 (10.2)Major bleeding with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)6 (10.2)Site of major bleed2/6 (33.3)Bronchopulmonary2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA0/6 (0)Major bleed clearly fatal or important contributor to death3/6 (50.0)Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60-107) / 80 (56-103)		
Administered during cardiac arrest, n (%)6 (10.2)Major bleeding Major bleeding with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%)6 (10.2)Site of major bleed Bronchopulmonary2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding Received red cell transfusion for bleeding Therapeutic anticoagulation at time of tPA Antiplatelet therapy at time of tPA Cumulative dose of tPA, mg, median (IQR)5/6 (83.3)Oxygenation and ventilation pre-tPA/post-tPA* PaO,, mm Hg, median (IQR)84 (60–107) / 80 (56–103)		
Major bleeding Major bleeding with 7 d after tPA, n (%)6 (10.2)Characteristics of bleeding, n/n bleed (%) Site of major bleed Bronchopulmonary2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding Received red cell transfusion for bleeding Antiplatelet therapy at time of tPA Major bleed clearly fatal or important contributor to death Cumulative dose of tPA, mg, median (IQR)5/6 (83.3)Oxygenation and ventilation pre-tPA/post-tPA* Pa _{Q_n} , mm Hg, median (IQR)84 (60–107) / 80 (56–103)		6 (10.2)
Characteristics of bleeding, n/n bleed (%) Site of major bleed Bronchopulmonary2/6 (33.3) (1/6 (16.7) (1/6 (16.7))Central nervous system1/6 (16.7) (1/6 (16.7))Gastrointestinal Mucocutaneous1/6 (33.3) (2/6 (33.3))Invasive hemostatic intervention for bleeding Received red cell transfusion for bleeding Therapeutic anticoagulation at time of tPA Major bleed clearly fatal or important contributor to death Cumulative dose of tPA, mg, median (IQR)2/6 (30.3) (2/6 (30.3))Oxygenation and ventilation pre-tPA/post-tPA* PaO_, mm Hg, median (IQR)84 (60–107) / 80 (56–103)	Major bleeding	· · · ·
Site of major bleed2/6 (33.3)Bronchopulmonary2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA0/6 (0)Major bleed clearly fatal or important contributor to death3/6 (50.0)Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60-107) / 80 (56-103)	Major bleeding with 7 d after tPA, n (%)	6 (10.2)
Bronchopulmonary2/6 (33.3)Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA0/6 (0)Major bleed clearly fatal or important contributor to death3/6 (50.0)Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60–107) / 80 (56–103)		
Central nervous system1/6 (16.7)Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA0/6 (0)Major bleed clearly fatal or important contributor to death3/6 (50.0)Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60-107) / 80 (56-103)		0/0 (00 0)
Gastrointestinal1/6 (16.7)Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA0/6 (0)Major bleed clearly fatal or important contributor to death3/6 (50.0)Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60–107) / 80 (56–103)		
Mucocutaneous2/6 (33.3)Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA2/6 (83.3)Antiplatelet therapy at time of tPA0/6 (0)Major bleed clearly fatal or important contributor to death3/6 (50.0)Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60–107) / 80 (56–103)		
Invasive hemostatic intervention for bleeding2/6 (33.3)Received red cell transfusion for bleeding2/6 (33.3)Therapeutic anticoagulation at time of tPA5/6 (83.3)Antiplatelet therapy at time of tPA0/6 (0)Major bleed clearly fatal or important contributor to death3/6 (50.0)Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60–107) / 80 (56–103)		2/6 (33.3)
Received red cell transfusion for bleeding 2/6 (33.3) Therapeutic anticoagulation at time of tPA 5/6 (83.3) Antiplatelet therapy at time of tPA 0/6 (0) Major bleed clearly fatal or important contributor to death 3/6 (50.0) Cumulative dose of tPA, mg, median (IQR) 50 (50-88) Oxygenation and ventilation pre-tPA/post-tPA* 84 (60–107) / 80 (56–103)		
Antiplatelet therapy at time of tPA 0/6 (0) Major bleed clearly fatal or important contributor to death 3/6 (50.0) Cumulative dose of tPA, mg, median (IQR) 50 (50-88) Oxygenation and ventilation pre-tPA/post-tPA* 84 (60–107) / 80 (56–103)	Received red cell transfusion for bleeding	2/6 (33.3)
Major bleed clearly fatal or important contributor to death 3/6 (50.0) Cumulative dose of tPA, mg, median (IQR) 50 (50-88) Oxygenation and ventilation pre-tPA/post-tPA* 84 (60–107) / 80 (56–103)	Therapeutic anticoagulation at time of tPA	5/6 (83.3)
Cumulative dose of tPA, mg, median (IQR)50 (50-88)Oxygenation and ventilation pre-tPA/post-tPA*84 (60–107) / 80 (56–103)Pa _{Oa} , mm Hg, median (IQR)84 (60–107) / 80 (56–103)	Antiplatelet therapy at time of tPA	
Oxygenation and ventilation pre-tPA/post-tPA* Pa _O , mm Hg, median (IQR) 84 (60–107) / 80 (56–103)	Najor bleed clearly tatal or important contributor to death	
Pa _{O_a} , mm Hg, median (IQR) 84 (60–107) / 80 (56–103)	Cumulative dose of tPA, mg, median (IQR)	U (88-UC) UC
F_{10} , median (100) 04 (00-107) 700 (30-103)		84 (60-107) / 80 (56-103)
	Fa_{O_2} , mining, median (IQR) Fi_{O_3} , median (IQR)	0.9 (0.6–1.0) / 1.0 (0.7–1.0)

(Continued)

Table 1. (Continued).

Characteristic	tPA Recipients ($n = 59$)
Pa _{O2} :FI _{O2} , median (IQR)	86 (69–157) / 102 (67–174)
Paco, mm Hg, median (IQR)	52 (45–71) / 54 (44–71)
Tidal volume, ml, median (IQR)	420 (385–500) / 440 (368–500)
Respiratory rate, breaths/min, median (IQR)	29 (22–30) / 30 (25–33)
Minute ventilation, L, median (IQR)	12.2 (10.0–14.6) / 12.8 (10.1–14.4)
Dead space, physiologic, ml, median (IQR)	297 (229-411) / 308 (236-388)
Therapies for refractory hypoxemia pre-tPA/post-tPA, n (%) [†]	00 (07 0) / 10 (07 1)
Prone positioning Neuromuscular blockade	22 (37.2) / 16 (27.1) 17 (28.8) / 20 (35.6)
Inhaled pulmonary vasodilators [‡]	12 (20.3) / 12 (20.3)
At least one therapy	30 (50.8) / 30 (50.8)
At least two therapies	14 (23.7) / 14 (23.7)
Number of vasopressors pre-tPA/post-tPA, n (%) [†]	
0	23 (39.0) /14 (23.7)
1	20 (33.9) / 11 (18.6)
2	8 (13.6) / 11 (18.6)
≥2	8 (13.6) / 26 (39.0)
VIS, median (IQR)	
0 h	6.0 (0-20.0)
6 h	7.6 (0–20.3)
12 h	5.3 (0-21.0)
24 h Outcomes	3.3 (0–14.9)
In-hospital death, n (%)	45 (76.3)
Discharged alive, n (%)	14 (23.7)
Length of stay among survivors, d, median (IQR)	13 (3–38)
Increase in Pa _O ::Fi _O ratio \geq 50%, <i>n</i> (%)*	8/42 (19.0)
Causes of Death, $n^{(8)}$	
Respiratory failure	40 (88.9)
Septic shock	25 (55.6)
Heart failure	8 (17.8)
Renal failure	15 (33.3)
Hepatic failure	2 (4.4)
Other	12 (26.7)
Previously reported, $n (\%)^{\parallel}$	17 (28.8)

Definition of abbreviations: BMI = body mass index; COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; IQR = interquartile range; Pa_{CO_2} = partial pressure of carbon dioxide; Pa_{O_2} : F_{IO_2} = ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; tPA = tissue plasminogen activator; VIS = vasoactive-inotropic score; VV-ECMO = venovenous extracorporeal membrane oxygenation.

*Oxygenation and ventilation values before and after tPA are derived from the closest arterial blood gas obtained within 48 hours before and after tPA receipt, respectively. These data were available for 42 of the 59 patients (71.2%) in the cohort.

[†]Therapies for refractory hypoxemia and number of vasopressors before and after tPA were assessed within 24 hours before and 24 hours after tPA receipt, respectively.

[‡]Inhaled pulmonary vasodilators include epoprostenol and nitric oxide.

§Patients may have had more than one cause of death.

^{II}A total of 17 patients were previously reported: 15 in a single-center case series by Orfanos and colleagues (6) and 2 in a single-center case series by Barrett and colleagues (7).

50 mg (IQR, 20–100), and the median infusion time was 2 hours (IQR, 1–2). A total of 45 patients (76.3%) who received tPA died during hospitalization.

Six patients (10.2%) experienced a major bleed within 7 days after tPA administration, four of whom (67%) bled within 2 days of tPA receipt (Table 2). Sites of major bleeding included the bronchopulmonary tree (n = 2), central nervous system (n = 1), gastrointestinal tract (n = 1), and mucocutaneous (n = 2). Among the six patients with a major bleed, five (83.3%) were receiving therapeutic anticoagulation at the time of tPA receipt (Table 2). All six patients with a major bleed died (median time from tPA receipt to death, 7 days [IQR, 5–16]).

Oxygenation and ventilation parameters were unchanged after tPA receipt, as was the proportion of patients who required

therapies for refractory hypoxemia (Table 1). Similarly, tPA did not affect the Pa_{O_2} :F I_{O_2} ratio longitudinally, either overall or in two prespecified subgroups: those with severe hypoxemia (Pa_{O_2} :F I_{O_2} <100) and D-dimer >10,000 ng/ml (13) at the time of tPA receipt (Figure 1). Results were similar when patients who received tPA during cardiac arrest were excluded. Pa_{O_2} :F I_{O_2} ratio increased by \geq 50% in only 8 of 42 patients (19.0%) with data available (Table 1). tPA also did not affect the amount of hemodynamic support as quantified by the VIS (Table 1).

In summary, we report the outcomes of 59 critically ill patients with COVID-19 who received fibrinolytic therapy with tPA. Despite the promising theoretical benefits of fibrinolytic therapy in COVID-19, administration of tPA did not improve oxygenation or hemodynamics in the patients in our cohort. We

Table 2. Characteristics of patients who experienced a major bleed

Age/ Sex	Invasive Mechanical Ventilation at Bleed?	Vasopressors at Bleed?	Site of Bleed(s)	Days from tPA to Bleed	Days from tPA to Death	On Therapeutic Anticoagulation at Bleed?	PTT at Bleed (s)	INR at Bleed	Platelet Count at Bleed (10 ⁹ /L)	pRBC Units Administered*	Invasive Hemostatic Intervention Performed?	Fatal or Important Contributor to Death?
57/M	Yes	Yes	NP	2	21	Yes, enoxaparin	79	1.4	120	2	Yes	No
58/M	Yes	No	Broncho pulmonary	1	8	Yes, heparin infusion	66	1.3	200	0	Yes	No
46/M	Yes	Yes	Broncho pulmonary and GI	0	0	No (receiving prophylactic-dose heparin)	39	1.1	205	0	No	Yes
37/M	Yes	Yes	Intracranial	6	6	Ýes, ´ enoxaparin	32	1.4	391	0	No	Yes
47/F	Yes	Yes	NP and OP	0	19	Yes, heparin infusion	70	1.1	149	1	No	No
59/M	Yes	Yes	Intracranial	4	4	Yes, heparin infusion	68	1.2	138	1	No	Yes

Definition of abbreviations: GI = gastrointestinal; INR = international normalized ratio; NP = nasopharyngeal; OP = oropharyngeal; pRBC = packed red blood cells; PTT = partial thromboplastin time; tPA = tissue plasminogen activator.

*pRBC transfusion was assessed within 2 days after the bleed.




Figure 1. Effect of tissue plasminogen activator (tPA) on hypoxemia. Bars represent median (interquartile range [IQR]) values for the ratio of the partial pressure of arterial oxygen to fraction of inspired oxygen (Pa_{O_2} : FI_{O_2}) before and after tPA receipt. "-1" represents the closest Pa_{O_2} : FI_{O_2} ratio obtained within 48 hours before tPA receipt. "+1," "+2," and "+3" represent the first three Pa_{O_2} : FI_{O_2} ratios obtained within 48 hours after tPA receipt. The median time from the "-1" Pa_{O_2} : FI_{O_2} ratio to tPA administration was 2.4 hours (IQR, 1.0–6.2). The median time from tPA administration to the "+1," "+2," and "+3" Pa_{O_2} : FI_{O_2} ratios was 3.0 (IQR, 1.3–9.1), 11.3 (IQR, 6.0–23.0), and 17.5 (IQR, 10.0–32.6) hours, respectively. The number of patients in the "All" category (n = 42) is less than 59 because 17 patients (28.8%) did not have arterial blood gas measurements obtained within 48 hours before and after tPA receipt.

found that major bleeding occurred in 6.8% of patients within 2 days of tPA administration and in 10.2% of patients within 7 days, all of whom died. Although a control arm was not available to directly compare bleeding risk in patients with similar disease severity who did or did not receive tPA, rates of major bleeding in this study were similar to those previously reported with tPA (14). Interestingly, five of the six patients who experienced a major bleed

were receiving therapeutic anticoagulation at the time of tPA receipt, suggesting the combination of these two therapies may result in a particularly high risk of bleeding.

We acknowledge several limitations, including observational design, absence of a control group, and heterogeneity of patients and tPA dosing regimens. Patients in this cohort were severely ill, with a median Pa_{O_2} :FI_{O2} ratio < 100

at the time of tPA receipt, a substantial number who required therapies for refractory hypoxemia, and a 76% in-hospital mortality rate. Indications for tPA administration were assessed via manual chart review; however, documentation of precise clinical decision-making was not always reliably captured. Arterial blood gases were not obtained at standardized time points, and factors such as changes in positioning (i.e., prone vs. supine) could have had an important influence of the Pa_{O_2} :FI_{O2} ratio in ways that were not captured by our data set. Many clinicians may have administered fibrinolytic therapy as an emergency treatment to save patients who were already dying. In fact, 10% of patients received tPA during a cardiac arrest. It is likely that some of the major bleeding events, particularly those detected more than 2 days after tPA administration, may have been due to other factors, particularly given the short half-life of tPA.

The possibility that tPA may confer benefits to select patients with COVID-19, perhaps if administered earlier in the disease course or to a more homogeneous group of patients, remains unknown. Randomized clinical trials of tPA in severely ill patients with COVID-19 (NCT04357730) will shed much needed light on the efficacy and safety of tPA in this setting.

Author disclosures are available with the text of this letter at www.atsjournals.org.

David J. Douin, M.D.* University of Colorado School of Medicine Aurora, Colorado

Shahzad Shaefi, M.D., M.P.H.[‡] Beth Israel Deaconess Medical Center Boston, Massachusetts

Samantha K. Brenner, M.D., M.P.H. Hackensack University Medical Center Hackensack, New Jersey

Shruti Gupta, M.D. Isabel Park, B.A. Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts

Franklin L. Wright, M.D. University of Colorado School of Medicine Aurora, Colorado

Kusum S. Mathews, M.D., M.P.H., M.S.C.R. Lili Chan, M.D., M.S.C.R. Icahn School of Medicine at Mount Sinai New York, New York

Hanny Al-Samkari, M.D. Massachusetts General Hospital Boston, Massachusetts

Sarah Orfanos, M.D. Jared Radbel, M.D.[§] *Rutgers Robert Wood Johnson Medical School New Brunswick, New Jersey*

David E. Leaf, M.D., M.M.Sc.[§] Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts

ORCID IDs: 0000-0002-5215-6854 (D.J.D.); 0000-0002-5747-2151 (S.G.); 0000-0002-8810-2794 (K.S.M.); 0000-0001-7875-090X (D.E.L.).

*Corresponding author (e-mail: david.douin@cuanschutz.edu). *These authors contributed equally to this work. *These authors contributed equally to this work.

References

- 1 Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020;18: 1738–1742.
- 2 Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *Lancet Respir Med* 2020;8:681–686.
- 3 Luo W, Yu H, Gou J, Li X, Sun Y, Li J, et al. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19) [preprint]. Preprints; 2020 [accessed 2020 Oct 14]. Available from: https://www. preprints.org/manuscript/202002.0407/v4.
- 4 Barrett CD, Moore HB, Moore EE, McIntyre RC, Moore PK, Burke J, et al. Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: scientific rationale and review. *Res Pract Thromb Haemost* 2020;4:524–531.
- 5 Moore HB, Barrett CD, Moore EE, Jhunjhnuwala R, McIntyre RC, Moore PK, et al. Study of alteplase for respiratory failure in SARS-Cov2/COVID-19: study design of the phase IIa STARS trial. Res Pract Thromb Haemost 2020;4:984–996.
- 6 Orfanos S, El Husseini I, Nahass T, Radbel J, Hussain S. Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space. *ERJ Open Res* 2020;6:00455–2020.
- 7 Barrett CD, Oren-Grinberg A, Chao E, Moraco AH, Martin MJ, Reddy SH, et al. Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: a case series. J Trauma Acute Care Surg 2020;89:453–457.
- 8 Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. STOP-COVID Investigators. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020;180:1–12.
- 9 Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al.; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380:1326–1335.
- 10 Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. *Pediatr Crit Care Med* 2010;11: 234–238.
- 11 Han J, Pinsino A, Sanchez J, Takayama H, Garan AR, Topkara VK, et al. Prognostic value of vasoactive-inotropic score following continuous flow left ventricular assist device implantation. J Heart Lung Transplant 2019; 38:930–938.
- 12 McIntosh AM, Tong S, Deakyne SJ, Davidson JA, Scott HF. Validation of the vasoactive-inotropic score in pediatric sepsis. *Pediatr Crit Care Med* 2017;18:750–757.
- 13 Schutte T, Thijs A, Smulders YM. Never ignore extremely elevated D-dimer levels: they are specific for serious illness. *Neth J Med* 2016; 74:443–448.
- 14 Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, *et al.* Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. *JAMA* 2014;311:2414–2421.

Copyright © 2021 by the American Thoracic Society